People: Charles River Laboratories International Inc (CRL.N)

CRL.N on New York Stock Exchange

15 Oct 2019
Change (% chg)

$0.17 (+0.13%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Milne, George 

Dr. George M. Milne Jr. Ph.D. is Lead Independent Director of Charles River Laboratories International Inc. He is a Venture partner of Radius Ventures LLC since 2003. Dr. Milne retired from Pfizer Inc. in 2002 after a 32-year career encompassing a broad array of management responsibilities, including as Executive Vice President, Pfizer Global Research and Development; President, Worldwide Strategic and Operations Management; President of Central Research with global responsibility for Pfizer's Human and Veterinary Medicine Research and Development; Senior Vice President of Pfizer Inc.; and a member of the Pfizer Management Council. Dr. Milne serves on the board of Aurinia Pharmaceuticals and several private companies and charitable organizations. In the past five years, he has served on the boards of Mettler-Toledo International, Inc. and Athersys, Inc. Dr. Milne has been a director since 2002. With his strong scientific background (including a Ph.D. in Organic Chemistry), his long tenure at Pfizer Inc., his work as a venture partner with Radius Ventures and through his service on multiple life science boards, Dr. Milne has a deep understanding of R&D processes and the services, tools, and technologies used in the life sciences industry, and supplies particular insights into industry drivers as well as the concerns and perspectives of the consumers of our products and services. In addition, he has had exposure to strategic and operational issues relevant to board leadership through his prior roles at Pfizer and on other public and private company boards. Dr. Milne also brings a unique industry perspective from his biomedical venture capital activities through Radius Ventures.

Basic Compensation

Total Annual Compensation, USD 90,000
Restricted Stock Award, USD 215,049
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 305,049

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Foster


David Smith


David Johst


William Barbo


Birgit Girshick


George Milne

As Of  29 Dec 2018